J. Schachter

J. Schachter, R. Feinmesser, A. Sulkes, 2004, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.

Gideon Rechavi, Victor G Prieto, Iris Barshack, 2013, The Journal of clinical investigation.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

J. Larkin, A. Ribas, C. Blank, 2019, The Lancet. Oncology.

Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients

E. Segal, B. Shalmon, J. Schachter, 2009, Journal of immunotherapy.

Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients

J. Schachter, G. Markel, M. Besser, 2018, Cancer Immunology, Immunotherapy.

Comment on "Perhaps not everyone knows that...", (Ann Oncol 2001; 12: 1186).

J. Schachter, A. Sulkes, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex

J. Schachter, J. Jacob-Hirsch, G. Markel, 2014, Open Biology.

Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

I. Barshack, J. Schachter, S. Kaech, 2019, Cell.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2017, The New England journal of medicine.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

D. Schadendorf, P. Ascierto, R. Dummer, 2017, European journal of cancer.

Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation

J. Schachter, Sharon Yunger, G. Markel, 2017, Front. Immunol..

Adoptive Cell Therapy for Metastatic Melanoma.

J. Schachter, G. Markel, M. Besser, 2017, Cancer journal.

Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.

J. Schachter, M. Besser, D. Zikich, 2016, Immunotherapy.

Identification of bacteria-derived HLA-bound peptides in melanoma

E. Ruppin, E. Segal, S. Peterson, 2021, Nature.

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme

J. Schachter, E. Ofek, G. Markel, 2015, Oncotarget.

Adoptive T cell therapy: An overview of obstacles and opportunities

J. Schachter, G. Markel, M. Besser, 2017, Cancer.

miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1

J. Schachter, G. Markel, R. Cohen, 2015, Oncotarget.

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

D. Schadendorf, K. Flaherty, J. Kim, 2021, Clinical Cancer Research.

Regulation of Cancer Aggressive Features in Melanoma Cells by MicroRNAs

Noam Shomron, Yona Keisari, Gal Markel, 2011, PloS one.

Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma

B. Shalmon, J. Schachter, G. Markel, 2013, PloS one.

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

B. Shalmon, J. Schachter, A. Nagler, 2013, Clinical Cancer Research.

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

N. Ajami, J. Wargo, I. Barshack, 2020, Science.

MDR1 expression identifies human melanoma stem cells.

Gideon Rechavi, Ninette Amariglio, J. Schachter, 2008, Biochemical and biophysical research communications.

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.

A. Hauschild, S. Ugurel, W. Guo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy

E. Fridman, J. Schachter, Sharon Yunger, 2019, Oncoimmunology.

Perioperative BRAF inhibitors in locally advanced stage III melanoma

J. Schachter, A. Nissan, G. Markel, 2017, Journal of surgical oncology.

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, The Lancet. Oncology.

ADAR1 regulates melanoma cell invasiveness by controlling beta3-integrin via microRNA-30 family members.

J. Schachter, G. Markel, M. Besser, 2020, American journal of cancer research.

ADAR1-mediated regulation of melanoma invasion

I. Barshack, J. Schachter, M. Bar‐eli, 2018, Nature Communications.

The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials

P. Ascierto, J. Larkin, F. Hodi, 2021, Melanoma research.

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

R. Dummer, J. Wolchok, A. Ribas, 2020, European journal of cancer.

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

P. Ascierto, A. Ribas, H. Schmidt, 2020, Journal for ImmunoTherapy of Cancer.

Mutagen-Specific Mutation Signature Determines Global microRNA Binding

J. Schachter, E. Eyal, N. Amariglio, 2011, PloS one.

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

J. Klijn, M. Piccart, R. Paridaens, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients

J. Schachter, G. Rechavi, A. Simon, 2009, Melanoma research.

CORRELATION BETWEEN TUMOUR AND SERUM β2m EXPRESSION IN PATIENTS WITH BREAST CANCER

J. Schachter, B. Kfir, R. Gal, 1996, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

Adoptive T-cell transfer in melanoma.

J. Schachter, G. Markel, M. Besser, 2013, Immunotherapy.

Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms

J. Schachter, G. Markel, R. Ortenberg, 2012, Clinical & developmental immunology.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The Lancet. Oncology.

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

C. Berking, G. Linette, J. Schachter, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

A. Hauschild, P. Ascierto, J. Larkin, 2019, European journal of cancer.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma

J. Schachter, T. Meirson, G. Markel, 2020, Cancers.

Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy.

J. Schachter, E. Ben-Ami, 2016, Melanoma management.

Standard and Nonstandard Applications of Sentinel Node-guided Melanoma Surgery

H. Gutman, M. Feinmesser, J. Schachter, 2000, World Journal of Surgery.

Immunotherapy of distant metastatic disease

A. Hauschild, D. Schadendorf, A. Eggermont, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2016 .

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.

J. Schachter, G. Markel, R. Shapira-Frommer, 2018, European journal of cancer.

Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells

I. Barshack, J. Schachter, G. Markel, 2018, Neoplasia.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2019, The Lancet. Oncology.

TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma

R. Berger, J. Schachter, J. Roszik, 2019, Cancer Immunology, Immunotherapy.

Primary Squamous Cell Carcinoma (SqCC) of the Breast

H. Gutman, J. Schachter, T. Menes, 2003, American journal of clinical oncology.

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies

J. Schachter, A. Nagler, A. Toren, 2022, Cells.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

J. Schachter, G. Markel, R. Shapira-Frommer, 2018, Autoimmunity reviews.

Lymphatic drainage to the popliteal basin in distal lower extremity malignant melanoma.

H. Gutman, J. Schachter, R. Hardoff, 2004, Archives of surgery.

A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study

I. Barshack, J. Schachter, E. Eyal, 2013, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy.

H. Gutman, J. Schachter, R. Gutman, 2002, Cancer.

Relationship of Tumorigenic Malignant Melanomas to Dermal Elastin: An Expression of Tumor/Stromal Interaction That May Be Related to Prognosis

H. Gutman, A. Tobar, M. Feinmesser, 2002, The American Journal of dermatopathology.

Sentinel node guided surgery for melanoma in the head and neck region

H. Gutman, J. Schachter, T. Shpitzer, 2004, Melanoma research.

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2021, Clinical Trials.

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, Journal of Clinical Oncology.

Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.

P. Ascierto, A. Ribas, H. Schmidt, 2022, Journal of Clinical Oncology.

Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, Journal of Clinical Oncology.

microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy

J. Schachter, G. Markel, R. Ortenberg, 2020, Cancer Immunology, Immunotherapy.

Adoptive Immunotherapy of Advanced Melanoma

J. Schachter, R. Shapira-Frommer, 2012, Current Treatment Options in Oncology.

Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective.

M. Papa, J. Schachter, G. Markel, 2012, Experimental and therapeutic medicine.

Adoptive transfer of tumor-infiltrating lymphocytes for melanoma: new players, old game.

J. Schachter, E. Ben-Ami, 2015, Immunotherapy.

Focus on Adoptive T Cell Transfer Trials in Melanoma

J. Schachter, Liat Hershkovitz, M. Besser, 2010, Clinical & developmental immunology.

A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma.

J. Schachter, A. Adler, A. Sulkes, 1998, Cancer biotherapy & radiopharmaceuticals.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2017, European journal of cancer.

CASE REPORT: Sentinel-node guided lymph-node dissection for Merkel cell carcinoma

H. Gutman, M. Feinmesser, J. Schachter, 1999 .

Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.

J. Schachter, G. Markel, M. Besser, 2009, Anticancer research.

CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases

J. Schachter, M. Besser, R. Shapira-Frommer, 2014, European Radiology.

Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.

H. Gutman, J. Schachter, R. Yerushalmi, 2008, Oncology reports.

Ras Oncoproteins Transfer from Melanoma Cells to T Cells and Modulate Their Effector Functions

J. Schachter, Y. Lerenthal, Y. Kloog, 2012, The Journal of Immunology.

LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component.

H. Gutman, J. Schachter, N. Wasserberg, 2002, Archives of surgery.

Topical Biafine and Lipiderm for the prevention of radiation dermatitis: a randomized prospective trial.

H. Gutman, J. Schachter, J. Sulkes, 2001, Oncology reports.

Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study

J. Lunceford, Chunsheng Zhang, J. Larkin, 2019, Prevention, Early Detection, and Interception.

KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma.

P. Ascierto, N. Ibrahim, A. Ribas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence.

H. Gutman, J. Schachter, A. Sulkes, 1999, Oncology reports.

Pigmented lesions clinic for early detection of melanoma: preliminary results.

J. Schachter, A. Orenstein, H. Trau, 2007, The Israel Medical Association journal : IMAJ.

Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy

J. Schachter, R. Shapira-Frommer, N. Asher, 2023, Cancers.

Adenosine-deaminase-acting-on-RNA-1 facilitates T-cell migration toward human melanoma cells.

J. Schachter, T. Meirson, G. Markel, 2022, Cancer immunology research.

Efficacy and Safety of Intravenous Immunoglobulin in Patients with Metastatic Melanoma

J. Schachter, Y. Shoenfeld, U. Katz, 2007, Annals of the New York Academy of Sciences.

Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study

J. Schachter, J. Grob, N. Basset-Seguin, 2019, Annals of Oncology.

Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

J. Larkin, A. Ribas, C. Blank, 2017 .

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma

J. Schachter, R. Shapira-Frommer, S. Laks, 2023, Frontiers in Oncology.

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2015, Journal of Translational Medicine.

Abstract CT042: Fecal microbiota transplantation (FMT) and re-induction of anti-PD-1 therapy in refractory metastatic melanoma patients - preliminary results from a phase I clinical trial (NCT03353402)

I. Barshack, J. Schachter, O. Koren, 2019, Clinical Trials.

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

A. Hauschild, D. Schadendorf, K. Flaherty, 2020 .

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

James R. Anderson, J. Larkin, A. Ribas, 2019, Clinical Trials.

Abstract CT134: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors

R. Murthy, I. Puzanov, J. Schachter, 2020 .

Initial TPS serum level as an indicator of relapse and survival in colorectal cancer.

J. Schachter, M. Mishaeli, I. Bayer, 1998, Anticancer research.

CEACAM1 Promotes Melanoma Cell Growth through Sox-2

I. Barshack, J. Schachter, G. Markel, 2014, Neoplasia.

PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy.

J. Schachter, A. Nissan, G. Lahat, 2023, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

CEACAM1 Promotes Melanoma Cell

I. Barshack, J. Schachter, G. Markel, 2014 .

Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma

J. Larkin, A. Ribas, C. Blank, 2015 .

Weird activity and the wandering spleen.

J. Schachter, U. Rubinstein, R. Bilik, 2005, The Israel Medical Association journal : IMAJ.

BRAF +/- MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006

A. Ribas, C. Blank, J. Schachter, 2018 .

Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free.

H. Gutman, M. Feinmesser, J. Schachter, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The New England journal of medicine.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

J. Larkin, A. Ribas, C. Blank, 2015, The New England journal of medicine.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ras Oncoproteins Transfer from Melanoma Cells to T Cells and Modulate Their Effector Functions

J. Schachter, Y. Lerenthal, Y. Kloog, 2012, The Journal of Immunology.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

P. Ascierto, R. Fisher, A. Ribas, 2019, Nature Medicine.

SUCCESSFUL PREGNANCY AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AND IFOSFAMIDE TREATMENT IN TWO POSTPUBERTAL WOMEN

J. Schachter, G. Rechavi, A. Toren, 2001, Pediatric hematology and oncology.

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

C. Berking, G. Linette, J. Schachter, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma

J. Schachter, N. Asher, A. Dori, 2023, Neurology.